# The Diagnostic Value of Onconeural Antibodies Depends on How They Are Tested

**Authors:** Raquel Ruiz-García, Eugenia Martínez-Hernández, Albert Saiz, Josep Dalmau, Francesc Graus

PMC · DOI: 10.3389/fimmu.2020.01482 · Frontiers in Immunology · 2020-07-14

## TL;DR

Testing for onconeural antibodies using only line blots can lead to misleading results, and combining line blots with immunohistochemistry improves diagnostic accuracy for paraneoplastic neurological syndrome.

## Contribution

The study demonstrates that using line blots alone for onconeural antibody testing significantly reduces diagnostic accuracy compared to combined methods.

## Key findings

- 48% of antibody-positive cases detected by both line blot and immunohistochemistry had a definite PNS diagnosis.
- Only 8% of cases positive by line blot alone had PNS, showing low diagnostic value of line blots alone.
- ZIC4 and Yo antibodies detected only by line blot had no association with PNS.

## Abstract

Detection of onconeural antibodies is important because establishes a definitive diagnosis of paraneoplastic neurological syndrome (PNS). The recommended method for diagnosis of onconeural antibodies is by immunohistochemistry on rodent brain sections and confirmation of results by immunoblot. However, in many diagnostic laboratories samples are only tested with commercial line blots. In this study we inquired whether this change in diagnostic methodology (line blot alone vs. combined immunohistochemistry and line blot) would affect the results. Among 439 samples examined by immunohistochemistry and a commercial line blot (Euroimmun, Lübeck, Germany) 96 (22%) were positive by line blot, and their clinical information was reviewed. Onconeural antibodies were detected by both assays in 46/96 (48%) patients (concordant group) whereas 50 (52%) were only positive by line blot (discordant group). In the concordant group 42/46 (91%) patients had a definite diagnosis of PNS whereas in the discordant group only 4/50 (8%) had PNS (p < 0.00001). None of the 14 patients with ZIC4 antibodies and 1/13 (8%) with Yo antibodies demonstrated only by line blot had PNS. These findings show a robust diagnostic value of combined diagnostic techniques, and both should be used to demonstrate onconeural antibodies, If antibody testing is performed only with line blot assay, positive bands should be confirmed by rodent brain immunohistochemistry. For ZIC4 or Yo antibody testing, line blot positivity with negative immunohistochemistry has no diagnostic significance, and for the rest of onconeural antibodies the predictive diagnostic value is low.

## Linked entities

- **Proteins:** ZIC4 (Zic family zinc finger 4), CDR2 (cerebellar degeneration related protein 2)
- **Diseases:** PNS (MONDO:0018215)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** ZIC4 (Zic family zinc finger 4) [NCBI Gene 84107], DNER (delta/notch like EGF repeat containing) [NCBI Gene 92737] {aka UNQ26, bet}, DPP6 (dipeptidyl peptidase like 6) [NCBI Gene 1804] {aka DPL1, DPPX, MRD33, VF2}, BMPER (BMP binding endothelial regulator) [NCBI Gene 168667] {aka CRIM3, CV-2, CV2}, IGLON5 (IgLON family member 5) [NCBI Gene 402665], TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, PCAT1 (prostate cancer associated transcript 1) [NCBI Gene 100750225] {aka PCA1, PCAT-1, PiHL}, AMPH (amphiphysin) [NCBI Gene 273] {aka AMPH1}, PNMA2 (PNMA family member 2) [NCBI Gene 10687] {aka MA2, MM2, RGAG2}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, SOX1 (SRY-box transcription factor 1) [NCBI Gene 6656], GAD2 (glutamate decarboxylase 2) [NCBI Gene 2572] {aka GAD65}, RCVRN (recoverin) [NCBI Gene 5957] {aka RCV1}, DPYSL5 (dihydropyrimidinase like 5) [NCBI Gene 56896] {aka CRAM, CRMP-5, CRMP5, CV2, RTSC4, Ulip6}, CDR2 (cerebellar degeneration related protein 2) [NCBI Gene 1039] {aka CDR62, Yo}
- **Diseases:** breast or ovarian cancer (MESH:D061325), -SCLC (MESH:D018288), sensory neuronopathy (MESH:D009134), epilepsia partialis continua (MESH:D017036), Chorea (MESH:D002819), carcinoma of unknown (MESH:D009382), cerebellar degeneration (MESH:D013132), Brainstem encephalitis (MESH:D004660), Myasthenia (MESH:D020294), Metabolic encephalopathy (MESH:D001928), Non-paraneoplastic syndrome (MESH:D010257), Neurological syndrome (MESH:D009461), gluten ataxia (MESH:D001259), spinal arteriovenous fistula (MESH:D001164), Subarachnoid hemorrhage (MESH:D013345), cramps (MESH:D009120), Polyneuropathy (MESH:D011115), Cancer (MESH:D009369), Neurotoxicity (MESH:D020258), Lambert Eaton myasthenic syndrome (MESH:D015624), Hodgkin lymphoma (MESH:D006689), Limbic encephalitis (MESH:D020363), cerebellar ataxia (MESH:D002524), lung cancer (MESH:D008175), -mediated (MESH:C567355), stiff-person syndrome (MESH:D016750), anxiety (MESH:D001007), dizziness (MESH:D004244), Sensory neuropathy (MESH:D009477), Neuromuscular (MESH:D009468), Thymoma (MESH:D013945), Sjogren syndrome (MESH:D012859), Alcoholic neuropathy (MESH:D020269), PCD (MESH:D020362), Small cell lung cancer (MESH:D055752), Brain metastasis (MESH:D009362), Epilepsy (MESH:D004827), Seizures (MESH:D012640), diplopia (MESH:D004172), Intestinal pseudo-obstruction (MESH:D007418), visual acuity (MESH:D014786), Morvan syndrome (OMIM:201300), Melanoma CV2 (MESH:D008545), Ovary (MESH:D010051), PNS (MESH:D020361)
- **Chemicals:** Triton X-100 (MESH:D017830), paraformaldehyde (MESH:C003043), PBS (-), nitrogen (MESH:D009584), hydrogen peroxide (MESH:D006861), sucrose (MESH:D013395)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** EM-H — Homo sapiens (Human), Childhood chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_1196), NSCLC CV2 — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_H623)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC7372120/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC7372120/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC7372120/full.md

---
Source: https://tomesphere.com/paper/PMC7372120